莫树锦 教授

研究范畴 <只提供英文版本>

1. EGFR-targeted therapy
2. Overcoming drug resistance
3. ALK and other oncogenic drivers
4. Immunotherapy and tumor vaccines
5. Liquid biopsy and biomarker development

履历概要 <只提供英文版本>

Professor Tony S.K. is the Li Shu Fan Medical Foundation endowed Professor and Chairman of Department of Clinical Oncology at The Chinese University of Hong Kong. His main research interest focuses on biomarker and molecular targeted therapy in lung cancer. He was the Principal Investigator and first author on the landmark IRESSA® Pan-Asia Study (IPASS), which was the first study that confirmed the application of precision medicine for advanced lung cancer. He has led and co-led multiple international phase III studies. These projects address various aspects on management of advanced lung cancer, and basically have defined the current practice.

Professor Mok has contributed to over 340 articles in international peer-reviewed journals, including the New England Journal of Medicine, Science, Lancet, Nature Medicine and Journal of Clinical Oncology, and published multiple editorials and textbooks. His work was recognized by numerous awards, his recent received awards: ESMO Lifetime Achievement Award in 2018, The 6th Kobayashi Foundation Award, Giant of Cancer Care, Bronze Bauhinia Star (BBS) by the Government of Hong Kong Special Administrative Region in 2022 and The Sixth Fok Ying-Tung Prize The World Outstanding Chinese Doctor Award in 2023. His article in the New England Journal of Medicine has been selected as one of the most “Notable Articles in 2017.” He is one of the “Highly Cited Researchers” by Clarivate Analytics for five consecutive years from 2018 to 2023.